Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02469246 · ClinicalTrials.gov registry record · Phase 3
Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 567
- Enrollment target
NCT02469246 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 567 participants.
The verdict
NCT02469246, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 567 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching abacavir/lamivudine (ABC/3TC) fixed-dose combination (FDC) tablets to emtricitabine/tenofovir alafenamide (F/TAF) FDC tablets versus maintaining ABC/3TC in human immunodeficiency virus type 1 (HIV-1) infected adults who are virologically suppressed on regimens containing ABC/3TC.
Interventions
- DRUG F/TAF
- DRUG F/TAF Placebo
- DRUG ABC/3TC
- DRUG ABC/3TC Placebo
- DRUG 3rd ARV agent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 567 participants |
| Start Date | 2015-06-29 |
| Est. Completion | 2019-03-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02469246
The ClinicalTrials.gov registry entry for NCT02469246 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 567 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which F/TAF is the first listed.
NCT02469246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02469246 about?
NCT02469246 is a clinical study titled "Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC". The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching abacavir/lamivudine (ABC/3TC) fixed-dose combination (FDC) tablets to emtricitabine/tenofovir alafenamide (F/TAF) FDC tablets versus maintaining ABC/3TC in human immunodeficiency virus type 1 (HI...
What is the current status of trial NCT02469246?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 567 participants. The study started on 2015-06-29. Estimated completion is 2019-03-13.
What interventions are being tested in trial NCT02469246?
The interventions under investigation include: F/TAF (DRUG), F/TAF Placebo (DRUG), ABC/3TC (DRUG), ABC/3TC Placebo (DRUG), 3rd ARV agent (DRUG).
Who is sponsoring clinical trial NCT02469246?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.